"Antipsychotic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
Descriptor ID |
D014150
|
MeSH Number(s) |
D27.505.696.277.950.040 D27.505.954.427.210.950.040 D27.505.954.427.700.872.331
|
Concept/Terms |
Antipsychotic Agents- Antipsychotic Agents
- Agents, Antipsychotic
- Antipsychotics
- Major Tranquilizers
- Tranquilizers, Major
- Tranquillizing Agents, Major
- Agents, Major Tranquillizing
- Major Tranquillizing Agents
- Neuroleptic Drugs
- Drugs, Neuroleptic
- Neuroleptics
- Tranquilizing Agents, Major
- Agents, Major Tranquilizing
- Major Tranquilizing Agents
- Antipsychotic Drugs
- Drugs, Antipsychotic
- Neuroleptic Agents
- Agents, Neuroleptic
Antipsychotic Effect- Antipsychotic Effect
- Effect, Antipsychotic
- Antipsychotic Effects
- Effects, Antipsychotic
|
Below are MeSH descriptors whose meaning is more general than "Antipsychotic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antipsychotic Agents".
This graph shows the total number of publications written about "Antipsychotic Agents" by people in this website by year, and whether "Antipsychotic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 3 | 0 | 3 |
1999 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2003 | 1 | 1 | 2 |
2004 | 2 | 0 | 2 |
2005 | 0 | 1 | 1 |
2006 | 2 | 1 | 3 |
2007 | 2 | 1 | 3 |
2008 | 4 | 2 | 6 |
2009 | 1 | 1 | 2 |
2010 | 2 | 2 | 4 |
2011 | 5 | 2 | 7 |
2012 | 6 | 1 | 7 |
2013 | 1 | 1 | 2 |
2014 | 4 | 0 | 4 |
2015 | 0 | 1 | 1 |
2017 | 2 | 0 | 2 |
2018 | 1 | 0 | 1 |
2019 | 1 | 1 | 2 |
2020 | 4 | 1 | 5 |
2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antipsychotic Agents" by people in Profiles.
-
Iwashita M, Yoshizawa M. Social-like responses are inducible in asocial Mexican cavefish despite the exhibition of strong repetitive behavior. Elife. 2021 09 20; 10.
-
Nikogosyan G, Orias D, Goebert D, Takeshita J, Wang M. Acute Aripiprazole-Associated Liver Injury. J Clin Psychopharmacol. 2021 May-Jun 01; 41(3):344-346.
-
Stahl SM, Sy S, Maguire GA. How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice. Acta Psychiatr Scand. 2021 02; 143(2):172-180.
-
Onyameh EK, Bricker BA, Eyunni SVK, Voshavar C, Gonela UM, Ofori E, Jenkins A, Ablordeppey SY. A study of the structure-affinity relationship in SYA16263; is a D2 receptor interaction essential for inhibition of apormorphine-induced climbing behavior in mice? Bioorg Med Chem. 2021 01 15; 30:115943.
-
Ngwa E, Winkfield D, Okunji P. Factors Affecting the Readmission Rates and Health Care Costs of Patients Hospitalized with Schizophrenia: Non-Adherence to Treatment and Increased Relapses. J Natl Black Nurses Assoc. 2020 Dec; 31(2):67-70.
-
Reddy HM, Poole JS, Maguire GA, Stahl SM. New Medications for Neuropsychiatric Disorders. Psychiatr Clin North Am. 2020 06; 43(2):399-413.
-
Jerome RN, Pulley JM, Sathe NA, Krishnaswami S, Dickerson AB, Worley KJ, Wilkins CH. Exploring Biologic Predictors Response Disparities to Atypical Antipsychotics among Blacks: A Quasi-Systematic Review. Ethn Dis. 2020; 30(Suppl 1):229-240.
-
Hassanzadah M, Bitar AH, Khanfar NM, Khasawneh FT, Lutfy K, Shankar GS. A retrospective cohort study of the prevalence of anxiety and agitation in schizophrenic smokers and the unmet needs of smoking cessation programs. Medicine (Baltimore). 2019 Oct; 98(40):e17375.
-
Bricker BA, Peprah K, Kang HJ, Ablordeppey SY. Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy. Pharmacol Biochem Behav. 2019 04; 179:55-62.
-
Maestri TJ, Mican LM, Rozea H, Barner JC. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission? Psychopharmacol Bull. 2018 03 13; 48(3):8-15.